Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NormoFlora UTI
- Development stage
- Unknown
- Lead developer
- MMC Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
NormoFlora UTI Tablets is a multi-ingredient nutraceutical supplement developed by MMC Pharmaceuticals for the maintenance of urinary tract health and the prevention of recurrent urinary tract infections (UTIs). The formulation typically contains D-mannose, cranberry extract, and probiotic strains such as *Lactobacillus rhamnosus* and *Lactobacillus reuteri*. D-mannose and cranberry proanthocyanidins (PACs) act by competitively inhibiting the attachment of P-fimbriated *Escherichia coli* to the urinary tract lining, facilitating their clearance through urination. The inclusion of probiotics aims to restore and maintain a healthy urogenital flora, creating a protective barrier against uropathogens.
- Brand names
- NormoFlora UTI TabletsNormoFlora UTI
02
Targets
FimH (Type 1 fimbrial adhesin)PapG (PapG adhesin)
Beyond the preview
Go deeper on NormoFlora UTI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NormoFlora UTI.